Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Reaction norm analysis reveals rapid shifts toward delayed maturation in harvested Lake Erie yellow perch (Perca flavescens).

Gíslason D, Heino M, Robinson BW, McLaughlin RB, Dunlop ES.

Evol Appl. 2019 Jan 30;12(5):888-901. doi: 10.1111/eva.12764. eCollection 2019 Jun.

2.

Identifying Subclinical Coronary Abnormalities and Silent Myocardial Ischemia After Arterial Switch Operation.

Tsuda T, Baffa JM, Octavio J, Robinson BW, Radtke W, Mody T, Bhat AM.

Pediatr Cardiol. 2019 Jun;40(5):901-908. doi: 10.1007/s00246-019-02085-4. Epub 2019 Mar 9.

PMID:
30852629
3.

Standardization of a Continuous Ramp Ergometer Protocol for Clinical Exercise Testing in Children.

Octavio JM, Folk AL, Falini L, Xie S, Goudie BW, Gidding SS, Robinson BW.

Pediatr Cardiol. 2019 Apr;40(4):834-840. doi: 10.1007/s00246-019-02079-2. Epub 2019 Mar 5.

PMID:
30834959
4.

Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE.

Biochem Biophys Res Commun. 2019 Mar 5;510(2):198-204. doi: 10.1016/j.bbrc.2019.01.057. Epub 2019 Jan 23.

PMID:
30685089
5.

Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine.

Ye L, Ma S, Robinson BW, Creaney J.

Expert Rev Respir Med. 2019 Feb;13(2):181-192. doi: 10.1080/17476348.2019.1563488. Epub 2018 Dec 30. Review.

PMID:
30596292
6.

Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors.

Chee J, Watson MW, Chopra A, Nguyen B, Cook AM, Creaney J, Lesterhuis WJ, Robinson BW, Lee YCG, Nowak AK, Lake RA, McDonnell AM.

BMC Res Notes. 2018 Dec 5;11(1):864. doi: 10.1186/s13104-018-3953-x.

7.

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.

Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA.

Oncogene. 2019 Mar;38(13):2241-2262. doi: 10.1038/s41388-018-0567-7. Epub 2018 Nov 26.

8.

Intraspecific brain size variation between coexisting sunfish ecotypes.

Axelrod CJ, Laberge F, Robinson BW.

Proc Biol Sci. 2018 Nov 7;285(1890). pii: 20181971. doi: 10.1098/rspb.2018.1971.

PMID:
30404883
9.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
10.

Combination immune checkpoint blockade as an effective therapy for mesothelioma.

Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Joost Lesterhuis W, Dick IM, Nowak AK, Robinson BW, Lake RA, Fisher SA.

Oncoimmunology. 2018 Jul 30;7(10):e1494111. doi: 10.1080/2162402X.2018.1494111. eCollection 2018.

PMID:
30288361
11.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
12.

Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.

Marini KD, Croucher DR, McCloy RA, Vaghjiani V, Gonzalez-Rajal A, Hastings JF, Chin V, Szczepny A, Kostyrko K, Marquez C, Jayasekara WSN, Alamgeer M, Boolell V, Han JZR, Waugh T, Lee HC, Oakes SR, Kumar B, Harrison CA, Hedger MP, Lorensuhewa N, Kita B, Barrow R, Robinson BW, de Kretser DM, Wu J, Ganju V, Sweet-Cordero EA, Burgess A, Martelotto LG, Rossello FJ, Cain JE, Watkins DN.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaat3504. doi: 10.1126/scitranslmed.aat3504.

PMID:
30045976
13.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R.

J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. Review.

PMID:
29966799
14.

Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.

Sneddon S, Dick I, Lee YCG, Musk AWB, Patch AM, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J.

Lung Cancer. 2018 May;119:64-70. doi: 10.1016/j.lungcan.2018.03.009. Epub 2018 Mar 9.

15.

Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing.

Patch AM, Nones K, Kazakoff SH, Newell F, Wood S, Leonard C, Holmes O, Xu Q, Addala V, Creaney J, Robinson BW, Fu S, Geng C, Li T, Zhang W, Liang X, Rao J, Wang J, Tian M, Zhao Y, Teng F, Gou H, Yang B, Jiang H, Mu F, Pearson JV, Waddell N.

PLoS One. 2018 Jan 10;13(1):e0190264. doi: 10.1371/journal.pone.0190264. eCollection 2018.

16.

A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.

Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ.

BMC Cancer. 2017 Oct 16;17(1):684. doi: 10.1186/s12885-017-3677-7.

17.

Comparative Analyses of Phenotypic Trait Covariation within and among Populations.

Peiman KS, Robinson BW.

Am Nat. 2017 Oct;190(4):451-468. doi: 10.1086/693482. Epub 2017 Aug 18.

PMID:
28937814
18.

Causes and Consequences of Behavioral Interference between Species.

Grether GF, Peiman KS, Tobias JA, Robinson BW.

Trends Ecol Evol. 2017 Oct;32(10):760-772. doi: 10.1016/j.tree.2017.07.004. Epub 2017 Aug 7. Review.

19.
20.

Flexible mate choice may contribute to ecotype assortative mating in pumpkinseed sunfish (Lepomis gibbosus).

Jarvis WMC, Comeau SM, Colborne SF, Robinson BW.

J Evol Biol. 2017 Oct;30(10):1810-1820. doi: 10.1111/jeb.13127. Epub 2017 Jun 29.

PMID:
28590579
21.

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.

Sneddon S, Patch AM, Dick IM, Kazakoff S, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J.

BMC Cancer. 2017 Jun 2;17(1):396. doi: 10.1186/s12885-017-3382-6.

22.

Calretinin as a blood-based biomarker for mesothelioma.

Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, Taeger D, Lehnert M, Kollmeier J, Bauer T, Musk AW, Robinson BWS, Brüning T, Creaney J.

BMC Cancer. 2017 May 30;17(1):386. doi: 10.1186/s12885-017-3375-5.

23.

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Creaney J, Dick IM, Leon JS, Robinson BW.

Cancer Genomics Proteomics. 2017 Mar-Apr;14(2):103-117.

24.

Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.

Creaney J, Robinson BWS.

Chest. 2017 Jul;152(1):143-149. doi: 10.1016/j.chest.2016.12.004. Epub 2016 Dec 19. Review.

25.

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.

Chee J, Robinson BW, Holt RA, Creaney J.

Chest. 2017 Apr;151(4):891-897. doi: 10.1016/j.chest.2016.10.007. Epub 2016 Oct 18. Review.

26.

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.

Greening DW, Ji H, Chen M, Robinson BW, Dick IM, Creaney J, Simpson RJ.

Sci Rep. 2016 Sep 8;6:32643. doi: 10.1038/srep32643.

27.

Severe odontogenic infection in pregnancy: a timely reminder.

Tocaciu S, Robinson BW, Sambrook PJ.

Aust Dent J. 2017 Mar;62(1):98-101. doi: 10.1111/adj.12463.

28.

Malignant pleural effusion: from bench to bedside.

Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT.

Eur Respir Rev. 2016 Jun;25(140):189-98. doi: 10.1183/16000617.0019-2016. Review. Erratum in: Eur Respir Rev. 2016 Sep;25(141):360. Eur Respir Rev. 2016 Sep;25(141):360.

29.

Immunotherapy for lung cancer.

Steven A, Fisher SA, Robinson BW.

Respirology. 2016 Jul;21(5):821-33. doi: 10.1111/resp.12789. Epub 2016 Apr 21. Review.

30.

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.

Creaney J, Dick IM, Musk AW, Olsen NJ, Robinson BW.

Biomarkers. 2016 Sep;21(6):551-61. doi: 10.3109/1354750X.2016.1160429. Epub 2016 Mar 24.

PMID:
27009350
31.

Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings.

Urtishak KA, Robinson BW, Rappaport EF, Sarezky MD, Biegel JA, Nichols KE, Wilmoth DM, Wang LS, Stern JW, Felix CA.

Pediatr Blood Cancer. 2016 Jul;63(7):1175-80. doi: 10.1002/pbc.25957. Epub 2016 Mar 21.

PMID:
26999444
32.

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.

Morré DJ, Hostetler B, Taggart DJ, Morré DM, Musk AW, Robinson BW, Creaney J.

Clin Proteomics. 2016 Feb 22;13:3. doi: 10.1186/s12014-016-9105-1. eCollection 2016.

33.

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.

Morré DJ, Hostetler B, Taggart DJ, Morré DM, Musk AW, Robinson BW, Creaney J.

Clin Proteomics. 2016 Jan 22;13:2. doi: 10.1186/s12014-016-9103-3. eCollection 2016. Erratum in: Clin Proteomics. 2016;13:3.

34.

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma.

Robinson C, Dick IM, Wise MJ, Holloway A, Diyagama D, Robinson BW, Creaney J, Lake RA.

BMC Cancer. 2015 Dec 18;15:983. doi: 10.1186/s12885-015-1953-y.

35.

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.

Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA.

Ann Oncol. 2015 Dec;26(12):2483-90. doi: 10.1093/annonc/mdv387. Epub 2015 Sep 18.

36.

Coronary artery problems late after arterial switch operation for transposition of the great arteries.

Tsuda T, Bhat AM, Robinson BW, Baffa JM, Radtke W.

Circ J. 2015;79(11):2372-9. doi: 10.1253/circj.CJ-15-0485. Epub 2015 Aug 19.

37.

Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.

Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L, Robinson BW, Nowak AK, Bosco A, Lake RA.

Sci Rep. 2015 Jul 21;5:12298. doi: 10.1038/srep12298.

38.

Restoration of defective cross-presentation in tumors by gemcitabine.

McDonnell AM, Joost Lesterhuis W, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BW.

Oncoimmunology. 2015 Feb 25;4(5):e1005501. eCollection 2015 May.

39.

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.

Creaney J, Ma S, Sneddon SA, Tourigny MR, Dick IM, Leon JS, Khong A, Fisher SA, Lake RA, Lesterhuis WJ, Nowak AK, Leary S, Watson MW, Robinson BW.

Oncoimmunology. 2015 May 11;4(7):e1011492. eCollection 2015 Jul.

40.

Correction: genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, Russo A, Hirvonen A, Casalone E, Tunesi S, Padoan M, Giordano M, Aspesi A, Casadio C, Ardissone F, Ruffini E, Betta PG, Libener R, Guaschino R, Piccolini E, Neri M, Musk AW, de Klerk NH, Hui J, Beilby J, James AL, Creaney J, Robinson BW, Mukherjee S, Palmer LJ, Mirabelli D, Ugolini D, Bonassi S, Magnani C, Dianzani I.

PLoS One. 2015 Jun 3;10(6):e0130109. doi: 10.1371/journal.pone.0130109. eCollection 2015. No abstract available.

41.

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.

Creaney J, Dick IM, Robinson BW.

Curr Opin Pulm Med. 2015 Jul;21(4):352-6. doi: 10.1097/MCP.0000000000000167. Review.

PMID:
26016578
42.

Discovery of new biomarkers for malignant mesothelioma.

Creaney J, Dick IM, Robinson BW.

Curr Pulmonol Rep. 2015;4(1):15-21. Review.

43.

Asbestos in Asia.

Leong SL, Zainudin R, Kazan-Allen L, Robinson BW.

Respirology. 2015 May;20(4):548-55. doi: 10.1111/resp.12517. Epub 2015 Mar 29. Review.

44.

Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.

Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJ, Moses EK, Melton PE, de Klerk N, Musk AW, Robinson BW, Creaney J.

Gene. 2015 May 25;563(1):103-5. doi: 10.1016/j.gene.2015.03.031. Epub 2015 Mar 18.

45.

Adaptive coherent averaging for real-time electrocardiogram enhancement.

Robinson BW, Saquib M.

Conf Proc IEEE Eng Med Biol Soc. 2014;2014:5048-51. doi: 10.1109/EMBC.2014.6944759.

PMID:
25571127
46.

The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.

Khong A, Cleaver AL, Fahmi Alatas M, Wylie BC, Connor T, Fisher SA, Broomfield S, Lesterhuis WJ, Currie AJ, Lake RA, Robinson BW.

BMC Cancer. 2014 Dec 17;14:969. doi: 10.1186/1471-2407-14-969.

47.

Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW.

Dis Markers. 2014;2014:413946. doi: 10.1155/2014/413946. Epub 2014 Nov 23.

48.

Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies.

Creaney J, Robinson BW.

Thorax. 2015 Apr;70(4):374-5. doi: 10.1136/thoraxjnl-2014-206564. Epub 2014 Dec 5. No abstract available.

PMID:
25480441
49.

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.

McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BW.

Eur J Immunol. 2015 Jan;45(1):49-59. doi: 10.1002/eji.201444722. Epub 2014 Dec 15.

50.

Chemotherapy enhances cross-presentation of nuclear tumor antigens.

Anyaegbu CC, Lake RA, Heel K, Robinson BW, Fisher SA.

PLoS One. 2014 Sep 22;9(9):e107894. doi: 10.1371/journal.pone.0107894. eCollection 2014.

Supplemental Content

Loading ...
Support Center